The 36-month beta value for FOLD is at 0.69. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for FOLD is 290.29M, and currently, shorts hold a 6.28% of that float. The average trading volume for FOLD on February 05, 2025 was 2.41M shares.
FOLD) stock’s latest price update
Amicus Therapeutics Inc (NASDAQ: FOLD) has seen a rise in its stock price by 0.80 in relation to its previous close of 9.76. However, the company has experienced a 2.58% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-03 that PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at the 21st Annual WORLDSymposium™ 2025, being held February 3-7, 2025 in San Diego, CA.
FOLD’s Market Performance
Amicus Therapeutics Inc (FOLD) has experienced a 2.58% rise in stock performance for the past week, with a 4.55% rise in the past month, and a -14.23% drop in the past quarter. The volatility ratio for the week is 2.59%, and the volatility levels for the past 30 days are at 3.12% for FOLD. The simple moving average for the past 20 days is 3.55% for FOLD’s stock, with a -4.98% simple moving average for the past 200 days.
Analysts’ Opinion of FOLD
Many brokerage firms have already submitted their reports for FOLD stocks, with Morgan Stanley repeating the rating for FOLD by listing it as a “Equal-Weight.” The predicted price for FOLD in the upcoming period, according to Morgan Stanley is $12 based on the research report published on December 13, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see FOLD reach a price target of $18. The rating they have provided for FOLD stocks is “Buy” according to the report published on September 06th, 2024.
Wells Fargo gave a rating of “Overweight” to FOLD, setting the target price at $18 in the report published on May 30th of the previous year.
FOLD Trading at 2.01% from the 50-Day Moving Average
After a stumble in the market that brought FOLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.88% of loss for the given period.
Volatility was left at 3.12%, however, over the last 30 days, the volatility rate increased by 2.59%, as shares surge +6.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.87% upper at present.
During the last 5 trading sessions, FOLD rose by +2.87%, which changed the moving average for the period of 200-days by -4.50% in comparison to the 20-day moving average, which settled at $9.50. In addition, Amicus Therapeutics Inc saw 4.44% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FOLD starting from Campbell Bradley L, who sale 7,500 shares at the price of $10.02 back on Dec 02 ’24. After this action, Campbell Bradley L now owns 886,654 shares of Amicus Therapeutics Inc, valued at $75,124 using the latest closing price.
BRADLEY CAMPBELL, the Director of Amicus Therapeutics Inc, proposed sale 7,500 shares at $9.98 during a trade that took place back on Dec 02 ’24, which means that BRADLEY CAMPBELL is holding shares at $74,850 based on the most recent closing price.
Stock Fundamentals for FOLD
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.89 for the gross margin
The net margin for Amicus Therapeutics Inc stands at -0.21. The total capital return value is set at 0.02. Equity return is now at value -67.09, with -13.50 for asset returns.
Based on Amicus Therapeutics Inc (FOLD), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at -0.06. The debt to equity ratio resting at 2.49. The interest coverage ratio of the stock is 0.22.
Currently, EBITDA for the company is -92.08 million with net debt to EBITDA at -22.95. When we switch over and look at the enterprise to sales, we see a ratio of 6.36. The receivables turnover for the company is 5.03for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.15.
Conclusion
In conclusion, Amicus Therapeutics Inc (FOLD) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
